Fluoroquinolones inhibit HCV by targeting its helicase

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 467-476

  Khan, Irfan A ^a,b   Siddiqui, Sammer ^a   Rehmani, Sadiq ^a   Kazmi, Shahana U ^b   Ali, Syed H ^a,c  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b UNIVERSITY OF KARACHI   (Pakistan)

^c DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL; BALOFLOXACIN; CINOXACIN; DIFLOXACIN; ENOXACIN; ENROFLOXACIN; FLEROXACIN; FLUMEQUINE; LUMIFLOXACIN; NONSTRUCTURAL PROTEIN 3; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; FLUOROQUINOLONES; HEPACIVIRUS; HUMANS; MICROBIAL SENSITIVITY TESTS; RNA HELICASES; RNA, VIRAL; TRANSFECTION; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84861707651     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1937     Document Type: Article

References (31)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1:74-81.
2. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
4. Higgins PG, Fluit AC, Schmitz FJ. Fluoroquinolones: structure and target sites. Curr Drug Targets 2003; 4:181-190. (Pubitemid 36553588)
5. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995; 270:21429-21432.
6. Richter S, Parolin C, Palumbo M, Palu G. Antiviral properties of quinolone-based drugs. Curr Drug Targets Infect Disord 2004; 4:111-116. (Pubitemid 38786650)
7. Portolani M, Pietrosemoli P, Cermelli C, et al. Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase. Antiviral Res 1988; 9:205-218.
8. Koukoulaki M, Apostolou T, Hadjiconstantinou V, Drakopoulos S. Impact of prophylactic administration of ciprofloxacin on BK polyoma virus replication. Transpl Infect Dis 2008; 10:449-451.
9. Josephson MA, Williams JW, Chandraker A, Randhawa PS. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis 2006; 8:95-101. (Pubitemid 43829486)
10. Ali SH, Chandraker A, DeCaprio JA. Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther 2007; 12:1-6. (Pubitemid 46340419)
11. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309:623-626. (Pubitemid 41033648)
12. Lindenbach BD, Meuleman P, Ploss A, et al. Cell culturegrown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 2006; 103:3805-3809. (Pubitemid 43376636)
13. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290:1972-1974.
14. Belon CA, Frick DN. Monitoring helicase activity with molecular beacons. Biotechniques 2008; 45:433-442.
15. Kingston RE. Introduction of DNA into Mammalian Cells. In Asubel FM, Brent R, Kingston RE, et al. (Editors). Current Protocols in Molecular Biology. John Wiley & Sons 2003.
16. Oniangue-Ndza C, Aus dem Siepen M, Lohmann V, et al. In vitro replicative properties of replicons constructed using sequence variants of the hepatitis C virus strain AD78 that caused a single-source outbreak of hepatitis C. Virus Res 2009; 142:1-9.
17. Frick DN. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr Issues Mol Biol 2007; 9:1-20. (Pubitemid 46139067)
18. Lam AM, Keeney D, Eckert PQ, Frick DN. Hepatitis C virus NS3 ATPases/helicases from different genotypes exhibit variations in enzymatic properties. J Virol 2003; 77:3950-3961. (Pubitemid 36350936)
19. Frick DN, Rypma RS, Lam AM, Gu B. The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently. J Biol Chem 2004; 279:1269-1280. (Pubitemid 38082651)
20. Witvrouw M, Daelemans D, Pannecouque C, et al. Broadspectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12. Antivir Chem Chemother 1998; 9:403-411. (Pubitemid 28446022)
21. Ikeda S, Yazawa M, Nishimura C. Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative. Antiviral Res 1987; 8:103-113. (Pubitemid 18002364)
22. Tsutsumi M, Takada A, Takase S, Sawada M. Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: a pilot study. J Gastroenterol Hepatol 1996; 11:1006-1011. (Pubitemid 26396235)
23. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003; 51 Suppl 1:1-11. (Pubitemid 36622099)
24. Liguori MJ, Blomme EA, Waring JF. Trovafloxacin-induced gene expression changes in liver-derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells. Drug Metab Dispos 2008; 36:223-233. (Pubitemid 351185733)
25. Ogino H, Fujii M, Ono M, et al. In vivo and in vitro effects of fluoroquinolones on lipopolysaccharide-induced proinflammatory cytokine production. J Infect Chemother 2009; 15:168-173.
26. Lawrence JW, Claire DC, Weissig V, Rowe TC. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol 1996; 50:1178-1188. (Pubitemid 26384856)
27. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
28. Komatsu M, Ishii T, Ono T, et al. Pilot study of ofloxacin and interferon-alpha combination therapy for chronic hepatitis C without sustained response to initial interferon administration. Can J Gastroenterol 1997; 11:507-511. (Pubitemid 27417460)
29. Negro F, Male PJ, Perrin L, Giostra E, Hadengue A. Treatment of chronic hepatitis C with alpha-interferon plus ofloxacin in patients not responding to alpha-interferon alone. J Hepatol 1998; 29:369-374. (Pubitemid 28396652)
30. Kojima H, Kaita KD, Hawkins K, Uhanova J, Minuk GY. Use of fluoroquinolones in patients with chronic hepatitis C virus-induced liver failure. Antimicrob Agents Chemother 2002; 46:3280-3282.
31. Belon CA, Frick DN. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol 2009; 4:277-293.